3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
6
Head and Neck Neoplasms
5
Carcinoma, Renal Cell
2
Stomach Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Diseases
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
29
Paclitaxel
7
Magnetic Resonance Spectroscopy
7
Cisplatin
7
Pemetrexed
6
Docetaxel
6
Carboplatin
6
Standard of Care
5
Radiotherapy
5
Nivolumab
5
Drug Therapy
5
Specimen Handling
4
Gemcitabine
4
Cetuximab
4
Blood Specimen Collection
4
epacadostat
3
X-Rays
3
Surveys and Questionnaires
3
Practice Guidelines as Topic
3
Oncolytic Virotherapy
3
Nicotine
3
Fluorouracil
3
Filgrastim
3
Cyclophosphamide
3
Bupropion
3
Bortezomib
3
Biopsy
3
spartalizumab
2
selpercatinib
2
sargramostim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
dostarlimab
×
Head & Neck
×
Clear all
NCT05060432
2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2
Active not recruiting
153 enrolled